PO.BCS01.07 · 生物信息与计算
基于空间转录组学的从组织学玻片估计三阴性乳腺癌肿瘤纯度
Spatial transcriptomics informed tumor purity estimation from histology slides for triple negative breast cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:肿瘤纯度,定义为肿瘤区域内恶性细胞的比例,是癌症研究和临床实践中的一个关键因素。准确的肿瘤纯度估计 (TPE) 在三阴性乳腺癌 (TNBC) 中至关重要,因为肿瘤异质性使诊断、生物标志物解读和治疗决策复杂化。传统的肿瘤纯度病理评估受限于观察者变异性和可扩展性。空间转录组学 (ST) 将全转录组数据与空间背景整合,实现了直接从H&E染色玻片对肿瘤纯度进行高分辨率、可扩展的估计。本研究开发并验证了ST监督的深度学习模型,用于空间解析的、可靠的TPE,以支持TNBC中更精确的临床评估和治疗指导。
方法:从Dartmouth-Hitchcock医学中心 (DHMC) 收集了25名TNBC患者的Visium ST数据和匹配的40×H&E全玻片图像,产生了120,973个50μm的Visium点,配有共配准的512×512像素H&E图块。使用经验证的DeepLabv3模型分割肿瘤区域。通过使用SCANVI将外部乳腺单细胞图谱与来自七名TNBC患者的内部单细胞RNA-seq数据整合,推导出细胞类型参考谱。使用Cell2Location将整合的单细胞数据映射到内部Visium切片上,以估计点层面的肿瘤细胞类型比例,作为监督标签。基于Virchow 2模型构建的深度学习模型 (VIDCellTyper) 经过训练和交叉验证,以预测点层面的肿瘤比例并生成空间解析的肿瘤纯度图。每个图块中来自HoVerNet的细胞计数通过细胞计数加权平均用于玻片层面的纯度计算。该工作流程在一个独立的TNBC队列 (n=29;DHMC和Cedars-Sinai医学中心) 上进行了验证,其中玻片层面的纯度由ST指导模型和HoVerNet的聚合图块层面预测得出。
结果:在肿瘤区域中,ST监督的深度学习模型实现了与点层面HoVerNet衍生TPE的0.88点层面纯度相关性 (p < 0.001)。在内部和外部队列 (n=29) 中聚合时,玻片层面的ST指导TPE与HoVerNet衍生TPE显示出0.83的Spearman相关性 (p < 0.001)。
结论:这项概念验证研究表明,ST可以指导计算模型直接从H&E玻片推导TPE,产生准确且空间解析的结果。ST指导的模型在独立的TNBC队列中具有泛化能力,展示了跨组织工作流程的稳健性。未来的工作将在临床相关背景下改进和验证该方法,包括治疗反应、预后以及化疗前后评估,以推进治疗评估和生物标志物开发的精确性。
查看英文原文 English abstract
Introduction: Tumor purity, defined as the proportion of malignant cells within a tumor region, is a critical factor in cancer research and clinical practice. Accurate tumor purity estimates (TPEs) are crucial in triple-negative breast cancer (TNBC), where tumor heterogeneity complicates diagnosis, biomarker interpretation, and therapeutic decisions. Traditional pathological assessment of tumor purity is limited by observer variability and scalability. Spatial transcriptomics (ST) integrates whole-transcriptome data with spatial context, enabling high-resolution and scalable estimation of tumor purity directly from H&E-stained slides. This study develops and validates ST-supervised deep learning models for spatially resolved, reliable TPEs that support more precise clinical evaluation and treatment guidance in TNBC.
Methods: Visium ST data and matched 40× H&E whole-slide images from 25 TNBC patients were collected from Dartmouth-Hitchcock Medical Center (DHMC), yielding 120,973 50‑µm Visium spots with co-registered 512×512-pixel H&E patches. Tumor regions were segmented using a validated DeepLabv3 model. Cell-type reference profiles were derived by integrating an external breast single-cell atlas with in-house single-cell RNA-seq data from seven TNBC patients using SCANVI. The integrated single-cell data were mapped onto in-house Visium sections with Cell2Location to estimate spot-level tumor cell-type proportions, serving as supervisory labels. A deep learning model (VIDCellTyper), built on the Virchow 2 model, was trained and cross-validated to predict spot-level tumor proportions and produce spatially resolved tumor purity maps. HoVerNet-derived cell counts from each patch were used for slide-level purity computation via cell-count-weighted averaging. The workflow was validated on an independent TNBC cohort (n=29; DHMC and Cedars-Sinai Medical Center), where slide-level purity was derived from aggregated patch-level predictions by the ST-informed model and HoVerNet.
Results: Across tumor regions, the ST-supervised deep learning model achieved a spot-level purity correlation of 0.88 (p < 0.001) with spot-level Hovernet-derived TPE. When aggregating across the internal and external cohorts (n=29), slide-level ST-informed TPE showed a Spearman correlation of 0.83 ( p < 0.001) with Hovernet-derived TPE.
Conclusion: This proof-of-concept study shows that ST can guide computational models to derive TPE directly from H&E slides, yielding accurate and spatially resolved results. The ST-guided model generalized across independent TNBC cohorts, demonstrating robustness across tissue workflows. Future work will refine and validate this approach in clinically relevant contexts, including therapy response, prognosis, and pre- versus post-chemotherapy evaluation, to advance precision in treatment assessment and biomarker development.
利益披露 Disclosure
M. Le, None..
V. Pujara, None..
I. Liao, None..
Y. Yuan, None..
J. Lownik, None..
G. Murray, None..
J. Bitar, None..
L. Chen, None..
P. Najafzadeh, None..
K. Dabirian, None..
D. Lin, None..
F. Kolling IV, None..
P. S. Shah, None..
J. Marotti, None..
X. Liu, None..
L. J. Vaickus, None..
K. Yao, None..
L. T. Vahdat, None..
J. Levy, None.